[1]
|
Murray, C.J., Ikuta, K.S., Sharara, F., et al. (2022) Global Burden of Bacterial Antimicrobial Resistance in 2019: A Sys-tematic Analysis. Lancet, 399, 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0
|
[2]
|
Mestrovic, T., Aguilar, G.R., Swetschinski, L.R., et al. (2022) The Burden of Bacterial Antimicrobial Resistance in the Who European Region in 2019: A Cross-Country Systematic Analysis. Lancet Public Health, 7, E897-E913.
https://doi.org/10.1016/S2468-2667(22)00225-0
|
[3]
|
Wang, Z., Koirala, B., Hernandez, Y., et al. (2022) A Natu-rally Inspired Antibiotic to Target Multidrug-Resistant Pathogens. Nature, 601, 606-611. https://doi.org/10.1038/s41586-021-04264-x
|
[4]
|
Escolà-Vergé, L., Los-Arcos, I. and Almirante, B. (2020) New Antibiotics for the Treatment of Infections by Multidrug-Resistant Microorganisms. Medicina Clínica, 154, 351-357. https://doi.org/10.1016/j.medcle.2019.11.005
|
[5]
|
Årdal, C., Balasegaram, M., Laxminarayan, R., et al. (2020) An-tibiotic Development—Economic, Regulatory and Societal Challenges. Nature Reviews Microbiology, 18, 267-274. https://doi.org/10.1038/s41579-019-0293-3
|
[6]
|
Paul, M., Carrara, E., Retamar, P., et al. (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Mul-tidrug-Resistant Gram-Negative Bacilli (Endorsed by European Society of Intensive Care Medicine). Clinical Microbiol-ogy and Infection, 28, 521-547.
https://doi.org/10.1016/j.cmi.2021.11.025
|
[7]
|
Abdelaziz, N.A., Elkhatib, W.F., Sherif, M.M., et al. (2022) In Sil-ico Docking, Resistance Modulation and Biofilm Gene Expression in Multidrug-Resistant Acinetobacter baumannii via Cinnamic and Gallic Acids. Antibiotics, 11, Article No. 870. https://doi.org/10.3390/antibiotics11070870
|
[8]
|
张怡敏. 十种常用中药单味、复方制剂对多重耐药鲍曼不动杆菌——体外抑菌作用的研究[D]: [硕士学位论文].咸阳: 西北农林科技大学, 2016.
|
[9]
|
Kyriakidis, I., Vasileiou, E., Pana, Z.D. and Tragiannidis, A. (2021) Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens, 10, Article No. 373. https://doi.org/10.3390/pathogens10030373
|
[10]
|
Jeon, J.H., Lee, J.H., Lee, J.J., et al. (2015) Structural Basis for Carbapenem-Hydrolyzing Mechanisms of Carbapenemases Conferring Antibiotic Resistance. International Journal of Molecular Sciences, 16, 9654-9692.
https://doi.org/10.3390/ijms16059654
|
[11]
|
De Oliveira, D.M.P., Forde, B.M., Kidd, T.J., et al. (2020) Antimicro-bial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews, 33, e00181-19. https://doi.org/10.1128/CMR.00181-19
|
[12]
|
Abdi, S.N., Ghotaslou, R., Ganbarov, K., et al. (2020) Acinetobacter baumannii Efflux Pumps and Antibiotic Resistance. Infection and Drug Resistance, 13, 423-434. https://doi.org/10.2147/IDR.S228089
|
[13]
|
Moubareck, C.A.and Halat, D.H. (2020) Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Anti-biotics, 9, Article No. 29.
https://doi.org/10.3390/antibiotics9030119
|
[14]
|
Harding, C.M., Hennon, S.W. and Feldman, M.F. (2018) Uncov-ering the Mechanisms of Acinetobacter baumannii Virulence. Nature Reviews Microbiology, 16, 91-102. https://doi.org/10.1038/nrmicro.2017.148
|
[15]
|
Gallagher, P. and Baker, S. (2020) Developing New Therapeutic Approaches for Treating Infections Caused by Multi-Drug Resistant Acinetobacter baumannii: Acinetobacter baumannii Therapeutics. Journal of Infection, 81, 857-861.
https://doi.org/10.1016/j.jinf.2020.10.016
|
[16]
|
Kaushik, V., Tiwari, M., Joshi, R. and Tiwari, V. (2022) Therapeu-tic Strategies against Potential Antibiofilm Targets of Multidrug-Resistant Acinetobacter baumannii. Journal of Cellular Physiology, 237, 2045-2063.
https://doi.org/10.1002/jcp.30683
|
[17]
|
王晓磊. 蟾酥与氨基糖苷类抗菌药物联合抗多重耐药鲍曼不动杆菌的实验研究[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2016.
|
[18]
|
卢珍. 蟾酥联合β-内酰胺类抗菌药物抗多重耐药鲍曼不动杆菌的实验研究[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2016.
|
[19]
|
Liu, C., Huang, H., Zhou, Q., et al. (2019) Antibacterial and Antibiotic Synergistic Activities of the Extract from Pithecellobium clypearia against Clinically Important Multidrug-Resistant Gram-Negative Bacteria. European Journal of Integrative Medicine, 32, Article ID: 100999. https://doi.org/10.1016/j.eujim.2019.100999
|
[20]
|
王洁, 朱俊豪, 张斌, 等. 能逆转细菌耐药性的中药的筛选[J]. 中国药学杂志, 2014, 49(21): 1892-1896.
|
[21]
|
李娟, 李小宁, 钟正灵, 等. 中药单体白花丹醌对鲍曼不动杆菌的耐药逆转作用[J]. 中国临床药理学与治疗学, 2015, 20(2): 155-159.
|
[22]
|
汪东海, 陈敏, 姜志强, 等. 黄芩苷消除鲍曼不动杆菌耐药质粒的实验研究[J]. 中国现代应用药学, 2012, 29(5): 400-404.
|
[23]
|
Sherif, M.M., Elkhatib, W.F., Khalaf, W.S., Elleboudy, N.S. and Abdelaziz, N.A. (2021) Multidrug Resistant Acinetobacter baumannii Biofilms: Evaluation of Phenotypic-Genotypic Association and Susceptibility to Cinnamic and Gallic Acids. Frontiers in Microbiology, 12, Article 716627. https://doi.org/10.3389/fmicb.2021.716627
|
[24]
|
谭俊青, 李蔼文, 王康椿, 等. 头孢哌酮-舒巴坦联合中药对泛耐药鲍曼不动杆菌抗菌活性的研究[J]. 检验医学, 2016, 31(5): 350-354.
|
[25]
|
潘杰, 苗霞, 刘启波, 等. 12种中药配方颗粒体外逆转临床常见细菌耐药性分析[J]. 检验医学, 2016, 31(6): 503-508.
|
[26]
|
许成勇, 谢伟鑫, 吴春洪, 等. 米诺环素等联合用药并配合中药麻黄升麻汤加减治疗多重耐药鲍曼不动杆菌肺炎疗效观察[J]. 中国临床新医学, 2019, 12(10): 1079-1082.
|
[27]
|
薛艳红. 中药肺炎合剂与西药联合治疗泛耐药鲍曼不动杆菌肺部感染临床观察[J]. 中国中医急症, 2015, 24(6): 1076-1078.
|
[28]
|
付玲, 邬海桥, 杨娟, 等. 清肺生脉汤对AECOPD多重耐药鲍曼不动杆菌感染的临床疗效观察[J]. 中药新药与临床药理, 2022, 33(1): 120-125.
|
[29]
|
张晓玲. 中西药组合对多重耐药鲍曼不动杆菌体外抑菌活性的研究[D]: [硕士学位论文]. 济南: 济南大学, 2014.
|
[30]
|
李晓君, 邓超, 谭俊青, 等. 黄连等五种中药颗粒剂对鲍曼不动杆菌生物膜耐药性及相关基因的作用分析[J]. 中医药临床杂志, 2022, 34(2): 313-317.
|
[31]
|
李新, 陈化禹, 杨桂芳, 等. 热毒宁与头孢哌酮钠/舒巴坦钠对泛耐药鲍曼不动杆菌的体外抑菌作用[J]. 山东医药, 2015, 55(34): 92-93.
|